GID7 Antibody

What is GID7 and what are its alternative names in research literature?

GID7 is a core component of the CTLH E3 ubiquitin-protein ligase complex. In research literature, GID7 is commonly referred to by several alternative names including WDR26, CDW2, MIP2 (Myocardial ischemic preconditioning upregulated protein 2), and GID complex subunit 7 homolog . When searching for research publications, it's advisable to include these alternative nomenclatures to ensure comprehensive coverage of the literature.

What are the key biological functions of GID7 that researchers should consider?

GID7/WDR26 functions primarily as:

• A G-beta-like protein involved in cell signal transduction

• A negative regulator in MAPK signaling pathways

• A scaffolding protein promoting G beta:gamma-mediated PLCB2 plasma membrane translocation

• A core component of the CTLH E3 ubiquitin-protein ligase complex

• A negative regulator of the canonical Wnt signaling pathway through preventing ubiquitination of beta-catenin

• A scaffold coordinating PI3K/AKT pathway-driven cell growth and migration

• A protective factor against oxidative stress-induced apoptosis

• A promoter of hypoxia-mediated autophagy and mitophagy

Understanding these diverse functions is critical when designing experiments to investigate specific GID7 pathways.

What species reactivity should researchers expect from commercially available GID7 antibodies?

Based on current commercial offerings, most GID7/WDR26 antibodies demonstrate reactivity with human samples, with predicted reactivity for mouse and rat samples . When selecting antibodies for non-human experimental systems, validation in the specific species is strongly recommended as cross-reactivity may vary between different antibody clones.

How should researchers validate the specificity of GID7 antibodies?

Validation of GID7 antibodies should employ multiple complementary approaches:

• Knockout (KO) cell lines: Generate GID7 knockout lines to confirm antibody specificity. This is particularly important as YCharOS research indicates many commercial antibodies lack adequate specificity, leading to off-target effects .

• Immunoblotting with recombinant proteins: Compare reactivity with purified GID7 protein versus other WD-repeat domain proteins.

• Immunoprecipitation followed by mass spectrometry: Confirm that the antibody pulls down GID7 specifically.

• Multiple antibody concordance: Compare results using antibodies raised against different epitopes of GID7.

• RNA interference: Correlate protein detection with GID7 knockdown efficiency.

What epitopes should be targeted for optimal GID7 antibody performance in different applications?

Based on available commercial antibodies, researchers should consider:

• For Western blot applications: Antibodies targeting sequences within amino acids 150-250 or 600-650 of human WDR26 have demonstrated efficacy .

• For immunoprecipitation studies: Antibodies against the region corresponding to amino acids 362-661 show better performance for protein-protein interaction studies .

• For studying specific isoforms: Target unique sequences that distinguish between ARMC8α and ARMC8β-associated GID complexes .

Multiple experimental applications may require different antibodies targeting distinct epitopes due to epitope accessibility variations between native and denatured states.

How should experiments be designed to distinguish between the different GID complex modules?

The GID complex engages two independent modules with distinct functions. To properly investigate these modules:

• Design co-immunoprecipitation assays that can specifically identify interactions between:

  • GID4 and ARMC8α (which interact) versus GID4 and ARMC8β (which don't interact)

  • WDR26/RanBP9 module versus ARMC8α/GID4 module

• When studying the core complex structure, consider that:

  • ARMC8α, but not ARMC8β, recruits GID4 to the core complex

  • Both ARMC8α and ARMC8β endogenous isoforms co-immunoprecipitate with HSS-tagged WDR26

• For functional studies, reconstitute hGID complexes containing either ARMC8α or ARMC8β to compare their GID4-dependent ubiquitination activity .

What controls are essential when using GID7 antibodies in ubiquitination assays?

Ubiquitination assays involving GID7 require rigorous controls:

How can researchers effectively study the GID7/WDR26 role in tumor development?

To investigate GID7/WDR26's role in tumorigenesis:

• Expression analysis:

  • Quantify WDR26 expression levels across tumor types and correlate with clinical outcomes

  • Compare expression between tumor and matched normal tissues using validated antibodies

• Functional assessment:

  • Examine HBP1 tumor suppressor degradation in response to WDR26 overexpression

  • Investigate whether WDR26 overexpression is sufficient to trigger HBP1 degradation in relevant cell lines

• Pathway analysis:

  • Assess impact on MAPK, Wnt/β-catenin, and PI3K/AKT pathways using phospho-specific antibodies

  • Analyze cell cycle progression in response to WDR26 modulation

• In vivo models:

  • Generate conditional knockout or overexpression mouse models to study tissue-specific effects

  • Evaluate tumor growth rates and metastatic potential in response to GID7 modulation

What technical considerations are important when using GID7 antibodies for immunofluorescence studies?

For optimal immunofluorescence results with GID7 antibodies:

• Fixation method comparison:

  • 4% paraformaldehyde fixation is commonly used for GID7/WDR26 detection

  • Compare with methanol fixation which may better preserve some epitopes

• Antigen retrieval:

  • For FFPE tissues, citrate buffer (0.01M, pH 6.0) with heat-induced epitope retrieval is recommended

  • Optimize retrieval time (typically 15-20 minutes) for specific tissue types

• Co-localization studies:

  • Include markers for known GID7 subcellular locations (primarily cytoplasmic)

  • Consider co-staining with other GID complex components to demonstrate functional associations

• Signal amplification:

  • For low expression systems, consider tyramide signal amplification

  • Use confocal microscopy to accurately determine subcellular localization

• Controls:

  • Include cells with GID7/WDR26 knockdown/knockout as negative controls

  • Use cells overexpressing GID7 as positive controls for antibody validation

How should researchers address background issues when using GID7 antibodies in Western blot applications?

To minimize background and optimize Western blot detection:

• Antibody concentration optimization:

  • Recommended starting dilution for Western blot is typically 0.4 μg/ml (1:1000-1:2000 dilution)

  • Perform titration experiments to identify optimal concentration for specific sample types

• Blocking optimization:

  • Test different blocking agents (BSA vs. non-fat dry milk)

  • Extend blocking time to 1-2 hours at room temperature or overnight at 4°C

• Washing protocol:

  • Increase number and duration of washes (5 washes of 5-10 minutes each)

  • Add 0.1-0.3% Tween-20 to wash buffer to reduce non-specific binding

• Expected band size interpretation:

  • The predicted molecular weight of GID7/WDR26 is 72 kDa, but it may appear at approximately 80 kDa on some gel systems

  • Verify bands by comparing with positive control samples (e.g., HeLa cell lysate)

What strategies can help resolve conflicting GID7 antibody data between different experimental techniques?

When facing discrepancies between different detection methods:

• Antibody epitope considerations:

  • Different antibodies may recognize distinct conformational states

  • Compare results from antibodies targeting different epitopes (N-terminal vs. C-terminal)

• Sample preparation effects:

  • Protein denaturation in Western blot versus native conditions in IP may affect epitope accessibility

  • Consider native versus reducing conditions for Western blot

• Cross-validation approaches:

  • Complement antibody-based detection with genetic approaches (siRNA, CRISPR-Cas9)

  • Use orthogonal methods (MS-based proteomics) to confirm findings

• Isoform-specific detection:

  • Determine if conflicting results might be due to differential detection of ARMC8α versus ARMC8β-associated GID complexes

  • Design isoform-specific detection strategies

How can advanced proteomics approaches enhance GID7 interaction studies beyond traditional immunoprecipitation?

Modern proteomics offers sophisticated approaches for studying GID7 interactions:

• Proximity-dependent biotin identification (BioID):

  • Express GID7 fused to a promiscuous biotin ligase to identify proximal proteins in living cells

  • Compare interactomes between different cellular compartments or conditions

• Cross-linking mass spectrometry (XL-MS):

  • Use chemical cross-linkers to stabilize transient GID7 interactions

  • Identify cross-linked peptides to map interaction interfaces at amino acid resolution

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Map conformational changes in GID7 upon binding to different partners

  • Identify regions involved in protein-protein interactions

• Thermal proteome profiling (TPP):

  • Monitor thermal stability shifts of GID7 and interacting proteins

  • Identify condition-dependent complex formation

What are the recommended approaches for investigating the substrate specificity of GID7-containing complexes?

To comprehensively characterize GID7 substrate recognition:

• Global proteomics comparing wild-type versus GID7 knockdown/knockout:

  • Quantify protein abundance changes using SILAC or TMT labeling

  • Identify proteins that accumulate upon GID7 depletion as potential substrates

• Ubiquitome analysis:

  • Enrich for ubiquitinated proteins using tandem ubiquitin binding entities (TUBEs)

  • Compare ubiquitination patterns between control and GID7-depleted cells

• In vitro reconstitution systems:

  • Reconstitute GID complexes containing either ARMC8α or ARMC8β

  • Test ubiquitination activity against candidate substrates

  • Compare GID4-dependent versus HBP1 ubiquitination

• Protein-protein interaction screens:

  • Screen for ARMC8α-interacting proteins to identify potential novel substrate receptors

  • Use yeast two-hybrid or mammalian two-hybrid systems to identify direct interactions

What experimental approaches could identify additional mammalian GID4-like substrate receptors?

Current research indicates no additional mammalian GID4-like substrate receptors have been detected using bioinformatic criteria . To identify potential novel receptors:

• Protein interaction screening:

  • Perform systematic screening for ARMC8α-interacting proteins

  • Use affinity purification-mass spectrometry (AP-MS) with ARMC8α as bait

• Domain-focused approaches:

  • Search for proteins containing Pro/N-binding pocket domains similar to GID4

  • Test their ability to interact with known GID complex components

• Functional genomics:

  • Conduct CRISPR screens to identify genes affecting GID complex-mediated degradation

  • Validate hits using biochemical interaction assays

• Comparative genomics:

  • Analyze evolutionary conservation patterns of GID complex components

  • Identify lineage-specific additions to the complex that might function as substrate receptors

How can researchers effectively characterize the distinct roles of ARMC8α and ARMC8β in GID complex function?

The functional differentiation between ARMC8α and ARMC8β represents an important research direction:

• Isoform-specific depletion:

  • Design siRNAs or CRISPR strategies targeting unique regions of each isoform

  • Evaluate differential effects on various cellular processes

• Reconstitution experiments:

  • In ARMC8-depleted cells, reconstitute expression with either ARMC8α or ARMC8β

  • Compare their ability to rescue different phenotypes

• Chimeric protein analysis:

  • Create chimeric proteins swapping domains between ARMC8α and ARMC8β

  • Identify domains responsible for GID4 recruitment specificity

• Structural biology approaches:

  • Determine structures of GID complexes containing either ARMC8α or ARMC8β

  • Identify structural differences that explain functional divergence

• Evolutionary analysis:

  • Compare ARMC8 isoforms across species to identify conserved functional divergence

  • Infer evolutionary history of the two isoforms

What are the standard protocols for GID7/WDR26 antibody applications?

What are the characterized domains of GID7/WDR26 important for antibody targeting?